Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Preferreds stayed the same.
521,365,212 left in the clip
I’d say it was absorbed amazingly well by the market. Plenty of buyers. It’s CDsll about timing and if a company needs to do it, then that’s how you do it.
NIHK appears to be building a very LEGITIMATE EV business. Also, the steps they have taken to create a friendly share structure tells me that they actually care about attracting investors and taking care of the ones they already have. In a nutshell, it appears that in addition to building EV, they are building shareholder VALUE. As investors, these are the ones we want to buy and hold on to.
Gotta admit. It’s pretty nice to see that stop sign no information replaced with pink current!
Congratulations to Dr. Koos & team. They did it. Now many brokerages can buy this where they couldn’t before. Pps will reflect.
Yes!!! So awesome!!
On August 17, 2021 the United States Patent and Trademark Office ( “USPTO”) issued Patent Number 11,090,332 B2 to Regen Biopharma, Inc. for “Antigen Specific MRNA Cellular Cancer Vaccines”.
Disclosed in the patented invention are antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGEN BIOPHARMA, INC.
Dated: August 25,2021 By: /s/ David Koos
David Koos
Chief Executive Officer
On August 17, 2021 the United States Patent and Trademark Office ( “USPTO”) issued Patent Number 11,090,332 B2 to Regen Biopharma, Inc. for “Antigen Specific MRNA Cellular Cancer Vaccines”.
Disclosed in the patented invention are antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGEN BIOPHARMA, INC.
Dated: August 25,2021 By: /s/ David Koos
David Koos
Chief Executive Officer
Good day here everyone. Slow and steady wins the race. $RGBP
I think I’ll buy some NIHK come Monday.
Candles are stacking. Lol
Hmmm…well, if that’s true then that’s absolutely humongous news. What page of the 10q did you read that?
Are we sure it isn’t just the “old” convertible debt that was paid off?
Im reading, “as of June 30th, 2021, we had convertible notes payable of $2,364,075”. A 6.9% reduction yoy though.
Why is this running so hard?
Buying any dip they want to give me.
Crazy price action
Damn! Audited financials. Only one reason to have that done. Uplisting! Minimum .01 required for QB
I think peeps saw the 350% gain and couldn’t resist taking profits. I’ll have some buy orders in tomorrow to get a good dollar cost average here. Amazing news though!
I’m looking for a penny plus on this first leg.
It’s a good sign though. Look at it this way. It means they missed the boat and thus demand is high because they now want in. AND we get free entertainment watching them suffer because they weren’t smart enough to load their shares earlier. FOMO in full effect. Time for them to slap the ask.
I thought that was Drys? Did ship do that too?
Lol.
Picked up another mil! Going pink current.
Oh great. You know what that means.
Ha ha! Try harder.
Yessir! Today’s news was the perfect primer so people can see first hand what Big Pharma is willing to pay for this tech
Yeah man! Super psyched I got some shares down here. Got a real good feeling about this one.
All systems go. T-minus 10…9…8…7…$….$$….$$$
Just slapped the ask. Liking the potential here.
Which will perform better percentage wise? The commons or preferreds? Today it seems like preferreds.
Lol. Go RGBP!
L2 thinning out! :-$
Pfizer to Buy Remaining Shares of Trillium Therapeutics
Source: Dow Jones News
By Dave Sebastian
Pfizer Inc. has agreed to buy shares it didn't already own in Trillium Therapeutics Inc., a company focused on developing therapies for cancer treatment, for an implied equity value of $2.26 billion.
The companies on Monday said Pfizer is paying $18.50 a share in cash. Trilium shares closed at $6.09 on Nasdaq on Friday.
The deal would boost Pfizer's oncology category with the addition of immuno-therapeutics for hematological malignancies, they said.
$18.50 per share cash. Let that sink in. What’s our share price currently with 24 patents and cutting edge mRNA research? Exactly.
I agree. The deal has already been done behind the scenes. Just waiting on pink current.
My only question is especial or negra?
They just got approved for one after 5 long years of waiting. There are 23 others also. I believe the link is posted here.
They’re gonna go higher on pink current status alone never mind the mRNA patent approvals and short squeeze potential. A buyout would send this into the stratosphere.